YKL-40

Biomarker1 paper1 finding

  • Human trial1

Interventions

1

Semaglutide

downin humans1

1 study

  1. Semaglutide decreases YKL-40 in humans (7%-10%).

    Reviewearly Alzheimer's diseaseCSF

    Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications · The journal of prevention of Alzheimer's disease · 24 Sep 2026

Semaglutide →

Latest

Nov 2025: 0Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 02

Related